RESUMO JUSTIFICATIVA E OBJETIVOS: A percepção da dor facial parece estar relacionada com respostas fisiológicas ao estresse e com o dimorfismo sexual. No entanto, a relação entre dor facial, secreção de cortisol e o sexo ainda foi pouco investigada. O objetivo deste estudo foi investigar as diferenças nos perfis de cortisol salivar matutino em homens e mulheres com ou sem sintomas de dor facial. MÉTODOS: Trinta e nove indivíduos que relataram dor facial e 33 controles sem dor, de ambos os sexos, participaram deste estudo. Os sintomas de dor facial foram avaliados utilizando o Eixo II do Critério de Diagnóstico para Pesquisa das Disfunções Temporomandibulares, que forneceu os escores de dor crônica. A saliva foi coletada dos participantes no turno matutino a fim de obter os picos de cortisol, sendo armazenada até utilização posterior. Os níveis salivares de cortisol foram avaliados por ensaio imunoenzimático. A análise estatística incluiu testes de hipóteses e ANOVA com nível de significância de 5%, e uma regressão logística binária que testou a associação entre o sexo, cortisol, e cada sintoma de dor facial. RESULTADOS: Não foi observada associação entre dor facial e o sexo. Os níveis de cortisol foram semelhantes entre indivíduos com ou sem dor facial, independentemente do sexo. O modelo ajustado mostrou que a maioria dos sintomas não teve associação com o sexo, independentemente dos níveis de cortisol. CONCLUSÃO: Nos indivíduos com e sem dor facial, a regulação dos níveis de cortisol salivar matutino ocorreu de forma semelhante em ambos os sexos.

ABSTRACT BACKGROUND AND OBJECTIVES: Facial pain seems to be related to physiological responses to stress and sexual dimorphism. However, the relationship among facial pain, cortisol secretion and gender has been poorly investigated. This study aimed to investigate differences in morning salivary cortisol profile between males and females either with or without perceived facial pain symptoms. METHODS: Participated in the study 39 individuals reporting facial pain and 33 painless controls of both genders. Facial pain symptoms were evaluated with Axis II Research Diagnostic Criteria for Temporomandibular Disorders, which has supplied chronic pain scores. Saliva was collected in the morning to obtain cortisol peaks, being stored for further use. Salivary cortisol levels were evaluated by immunosorbent assay. Statistical analysis has included hypotheses tests and ANOVA with significance level of 5% and a binary logistic regression, which has tested the association between gender, cortisol and each facial pain symptom. RESULTS: There has been no association between facial pain and gender. Cortisol levels were similar among individuals with and without facial pain, regardless of gender. The adjusted model has shown that most symptoms were not associated to gender, regardless of cortisol levels. CONCLUSION: In individuals with and without facial pain symptoms, morning salivary cortisol levels regulation has been similar for both genders.

OBJETIVO: Avaliar as soluções anestésicas utilizadas por um grupo de cirurgiões-dentistas e o nível de conhecimento desses profissionais sobre riscos associados a essas substâncias. MÉTODOS: Cento e vinte e quatro (124) cirurgiões-dentistas da rede privada do município de São Luís (Maranhão, Brasil) responderam um questionário contendo perguntas relativas às soluções de escolha, aos critérios de escolha de anestésicos locais e vasoconstritores e à avaliação do conhecimento sobre os efeitos colaterais associados às substâncias. RESULTADOS: Os resultados obtidos foram analisados utilizando-se estatística descritiva. Observou-se que a maior parte dos cirurgiões-dentistas optaram por anestésicos locais em concentrações menos tóxicas, como a mepivacaína 2% e a lidocaína 2%, porém se verificou que a maioria dos profissionais optaram pelo mesmo vasoconstritor (epinefrina) em soluções de segunda escolha. Os principais critérios de escolha das soluções anestésicas foram a duração do procedimento e as características do paciente. Analisando os dados em conjunto, os cirurgiões-dentistas pareceram conhecer alguns efeitos colaterais associados a vasoconstritores, porém demonstraram uma deficiência no conhecimento de sinais e sintomas relacionados à sobredosagem de anestésicos locais. CONCLUSÃO: Concluiu-se que o grupo de cirurgiões-dentistas envolvido no presente estudo apresentou conhecimento limitado em relação à toxicidade de anestésicos locais, bem como contradição em relação à escolha de vasoconstritores. Estratégias para aprofundar o conhecimento sobre anestésicos locais e/ou vasoconstritores de profissionais da rede privada são necessárias.

OBJECTIVE: To evaluate the knowledge of dentists about signs and symptoms that may be indicative of systemic toxicity associated with the use of local anesthetic solutions. METHODS: One hundred and twenty-four (124) dentists from private clinics in São Luís (Maranhão, Brazil) answered a questionnaire regarding the choice of solutions, selection criteria for local anesthetics and vasoconstrictors, and side effects associated with these substances. Results were analyzed by using descriptive statistics. RESULTS: Although most respondents reported being likely to choose local anesthetics at less toxic concentrations (including 2% mepivacaine or lidocaine), they were also likely to have similar vasoconstrictor solutions (epinephrine) as the second choice. The main selection criteria of anesthetic solutions reported were the duration of procedures and patients' individual characteristics. In general, dentists demonstrated being aware of some side effects associated with vasoconstrictors; however, they showed a lack of knowledge regarding signs and symptoms related to an overdose of local anesthetics. CONCLUSION: The group of dentists involved in this study showed limited knowledge about the toxicity of local anesthetics, as well as some inconsistent background over the choice of vasoconstrictors. Thus, strategies are required towards improving the knowledge of professionals from private dental clinics regarding local anesthetics and/or vasoconstrictors.

Salivary IgA can serve as a first line of defense against pathogens that colonize and invade mucosal surfaces and may be protective against periodontal disease. The aim of this study was to assess salivary immunoglobulin A levels in diabetic and non-diabetic patients with different periodontal treatment needs. The Periodontal Screening & Recording (PSR) system was used to evaluate the periodontal treatment needs of 41 diabetic and 42 non-diabetic patients. Unstimulated whole saliva was collected from each patient immediately before clinical examination and stored at -20 °C until analysis. Salivary immunoglobulin A (s-IgA) levels were determined using an enzyme-linked immunosorbent assay, and values were expressed as optical density. Diabetic and non-diabetic patients were compared using clinical and laboratory data. PSR data indicated that periodontal disease was more frequent and more severe in diabetic patients. A higher prevalence of codes 3 and 4 was observed in diabetics as compared with non-diabetics (odds ratio = 2, P < 0.05). Furthermore, non-diabetic patients had more healthy sextants (code 0) than did diabetic patients. Over half of diabetic patients (∼54%) presented with s-IgA levels that were lower than the normal range (optical density from 0.4 nm to 0.6 nm; P < 0.05). In addition, diabetic patients showed a higher variability in s-IgA levels as compared with non-diabetic patients. In conclusion, diabetic individuals had lower s-IgA levels, more-frequent and more-severe periodontal disease, and a greater need for periodontal treatment as compared with non-diabetic patients.